儿童重度睑缘角结膜炎——多伦多经验
该回顾性连续队列研究纳入2006至2021年加拿大多伦多儿童医院角膜专业组197例(315眼)重度睑缘角结膜炎(BKC)患儿,报告其临床特征与治疗结局;91%患儿达完全缓解,23%使用全身抗生素者出现病情复发,其中75%发生于停药后第一年内。
要点
- 重度BKC患儿中83%存在角膜瘢痕、49%有新生血管形成,28%初诊时BCVA差于0.3 logMAR。
- 72%患儿需全身抗生素治疗,其中23%出现需升级治疗的复发,75%的复发出现在停药后第一年内。
- 91%患儿达完全缓解,即无疾病活动且不使用局部激素或全身抗生素。
核心结论
- BKC是儿童期的严重疾病,可能造成不可逆的眼部病变和视力丧失,中央瘢痕和散光可影响相当比例患儿的视力,因此需要早期识别和治疗以降低疾病负担。
- 密切随访至关重要,因为约四分之一患儿可能出现病情复发,尤其在停药后第一年内。
- 大多数重度BKC患儿需要局部激素联合全身抗生素以控制疾病活动。
研究设计与样本
- 回顾性连续队列研究,纳入2006年至2021年间就诊于加拿大多伦多儿童医院角膜专业组、年龄小于18岁的BKC患儿。
- 重度BKC定义为BKC伴炎症、新生血管形成、瘢痕、变薄和脂质沉积并累及周边和/或中央角膜,且随访至少6个月。
- 共从2542例睑缘炎患者中识别出197例重度BKC患儿(315眼)。
- 分析内容包括基本人口学资料、最佳矫正视力(BCVA)、屈光不正、疾病侧别、抗生素治疗类型与疗程、复发率及角膜受累范围。
主要发现
- 首次就诊时平均年龄为7.6岁,女性占优势,比例为2:1。
- 就诊时65%有睑板腺囊肿病史,28%的BCVA差于0.3 logMAR,末次随访时该比例改善至17%(P = .007)。
- 累及周边和中央角膜的最突出角膜病变为瘢痕(83%)和新生血管形成(49%)。
- 142例(72%)需要全身抗生素(阿奇霉素、克拉霉素、红霉素或多西环素),其中23%出现需升级治疗(局部激素和/或全身抗生素)的复发,75%的复发出现在停药后第一年内。
- 91%的患者达到完全缓解,定义为无疾病活动且不使用局部激素或全身抗生素治疗;15例需要手术干预。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report on the clinical characteristics and treatment outcomes of a large cohort of pediatric patients who presented with severe blepharokeratoconjunctivitis (BKC). DESIGN: Retrospective consecutive cohort study. SUBJECTS: Patients aged under 18 years with BKC presented to the Cornea Service at the Hospital for Sick Children, Toronto, Canada, between 2006 and 2021. METHODS: Children with severe BKC, defined as BKC with inflammation, new vessel formation, scarring, thinning, and lipid deposits affecting the peripheral and/or central cornea, and a follow-up of at least 6 months were included. Basic demographics, best corrected visual acuity (BCVA), refractive error, disease laterality, type and duration of antibiotic therapy, flare-up rate, and extent of corneal involvement were analyzed. MAIN OUTCOME MEASURES: BCVA, refraction, extent of corneal involvement, procedures, flare-up of BKC, and time to flare-up rate after cessation of systemic antibiotics treatment. RESULTS: Out of 2542 patients with blepharitis, 197 patients (315 eyes) were identified with severe BKC. The mean age at the first presentation was 7.6 years, with a 2:1 female predominance. At the presentation, 65% had a history of chalazion, and 28% had BCVA worse than 0.3 logMAR, which improved to 17% at final follow-up (P = .007). The most striking corneal pathologies affecting the peripheral and central cornea were scarring (83%) and new vessel formation (49%). One hundred forty-two patients (72%) required systemic antibiotics (azithromycin, clarithromycin, erythromycin, or doxycycline), of whom 23% experienced flare-ups requiring an escalation in treatment with topical steroids and/or systemic antibiotics, and 75% of these occurred within the first year of treatment cessation. Ninety-one percent of patients achieved complete response, defined as no disease activity and no use of topical steroids or systemic antibiotic treatment. Fifteen patients required surgical intervention. CONCLUSIONS: BKC is a serious disease in children, potentially causing irreversible ocular morbidity and vision loss. Central scarring and astigmatism can affect vision in a significant proportion of children. Therefore, early identification and treatment are necessary to reduce disease morbidity. Close follow-up is crucial as one in four patients may experience a flare-up, especially within the first year of treatment cessation. Most patients with severe BKC require both topical steroids and systemic antibiotics to control disease activity.
引用
- Barbara R, Khalili S, Rachdan D, et al. Severe Blepharokeratoconjunctivitis in Children-The Toronto Experience. Am J Ophthalmol. 2025. PMID: 41125217. doi:10.1016/j.ajo.2025.10.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。